HUP0401046A3 - Liquid formulation comprising cetuximab and a fatty acid ester of polyoxyethylene sorbitan - Google Patents

Liquid formulation comprising cetuximab and a fatty acid ester of polyoxyethylene sorbitan

Info

Publication number
HUP0401046A3
HUP0401046A3 HU0401046A HUP0401046A HUP0401046A3 HU P0401046 A3 HUP0401046 A3 HU P0401046A3 HU 0401046 A HU0401046 A HU 0401046A HU P0401046 A HUP0401046 A HU P0401046A HU P0401046 A3 HUP0401046 A3 HU P0401046A3
Authority
HU
Hungary
Prior art keywords
cetuximab
fatty acid
acid ester
polyoxyethylene sorbitan
liquid formulation
Prior art date
Application number
HU0401046A
Other languages
English (en)
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of HUP0401046A2 publication Critical patent/HUP0401046A2/hu
Publication of HUP0401046A3 publication Critical patent/HUP0401046A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
HU0401046A 2001-07-13 2002-06-18 Liquid formulation comprising cetuximab and a fatty acid ester of polyoxyethylene sorbitan HUP0401046A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10133394A DE10133394A1 (de) 2001-07-13 2001-07-13 Flüssige Formulierung enthaltend Cetuximab
PCT/EP2002/006696 WO2003007988A1 (de) 2001-07-13 2002-06-18 Flüssige formulierung enthaltend cetuximab und einen polyoxyethylensorbitanfettsäureester

Publications (2)

Publication Number Publication Date
HUP0401046A2 HUP0401046A2 (en) 2006-04-28
HUP0401046A3 true HUP0401046A3 (en) 2006-11-28

Family

ID=7691220

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0401046A HUP0401046A3 (en) 2001-07-13 2002-06-18 Liquid formulation comprising cetuximab and a fatty acid ester of polyoxyethylene sorbitan

Country Status (18)

Country Link
US (1) US20040170632A1 (hu)
EP (1) EP1406658A1 (hu)
JP (1) JP2004536129A (hu)
KR (1) KR20040018458A (hu)
CN (1) CN1231264C (hu)
AR (1) AR039358A1 (hu)
BR (1) BR0211060A (hu)
CA (1) CA2453342A1 (hu)
CZ (1) CZ2004189A3 (hu)
DE (1) DE10133394A1 (hu)
HU (1) HUP0401046A3 (hu)
MX (1) MXPA04000340A (hu)
PE (1) PE20030433A1 (hu)
PL (1) PL364599A1 (hu)
RU (1) RU2004102395A (hu)
SK (1) SK862004A3 (hu)
WO (1) WO2003007988A1 (hu)
ZA (1) ZA200401161B (hu)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3417875T3 (da) * 2003-02-10 2020-08-31 Biogen Ma Inc Immunglobulinformulering og fremgangsmåde til fremstilling deraf
DE10355251A1 (de) * 2003-11-26 2005-06-23 Merck Patent Gmbh Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
DE10355904A1 (de) 2003-11-29 2005-06-30 Merck Patent Gmbh Feste Formen von anti-EGFR-Antikörpern
AU2005211890B2 (en) * 2004-02-12 2011-07-28 Merck Patent Gmbh Highly concentrated liquid formulations of anti-EGFR antibodies
MXPA06012145A (es) * 2004-04-27 2007-01-31 Wellstat Biologics Corp Tratamiento del cancer utilizando virus y camptotecinas.
JP2008519757A (ja) * 2004-11-12 2008-06-12 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 抗ｅｇｆｒ抗体の固形物
CN101163468A (zh) * 2005-02-28 2008-04-16 卫材R&D管理有限公司 磺酰胺化合物的新联合用途
NZ570381A (en) 2006-02-09 2011-02-25 Daiichi Sankyo Co Ltd Anti-cancer pharmaceutical composition
WO2007128557A1 (en) 2006-05-03 2007-11-15 Bayer Schering Pharma Aktiengesellschaft Combination of an anti edb fibronectin domain antibody l19-sip and an anti-egfr antibody
AU2007307107B2 (en) * 2006-10-06 2011-11-03 Amgen Inc. Stable antibody formulations
TW200833357A (en) * 2006-10-20 2008-08-16 Amgen Inc Stable polypeptide formulations
CN107773755B (zh) * 2016-08-31 2021-06-22 上海津曼特生物科技有限公司 抗表皮生长因子受体单克隆抗体的注射液制剂
WO2018211517A1 (en) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
KR20210024082A (ko) 2018-06-25 2021-03-04 제이씨알 파마 가부시키가이샤 단백질 함유 수성 액제

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) * 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5945098A (en) * 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
JPH11507535A (ja) * 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
PT1516628E (pt) * 1995-07-27 2013-09-24 Genentech Inc Formulação de proteína liofilizada isotónica estável

Also Published As

Publication number Publication date
HUP0401046A2 (en) 2006-04-28
BR0211060A (pt) 2004-07-20
MXPA04000340A (es) 2004-05-04
AR039358A1 (es) 2005-02-16
KR20040018458A (ko) 2004-03-03
DE10133394A1 (de) 2003-01-30
CA2453342A1 (en) 2003-01-30
EP1406658A1 (de) 2004-04-14
SK862004A3 (en) 2004-07-07
PL364599A1 (en) 2004-12-13
ZA200401161B (en) 2004-10-22
US20040170632A1 (en) 2004-09-02
WO2003007988A1 (de) 2003-01-30
CN1527724A (zh) 2004-09-08
JP2004536129A (ja) 2004-12-02
CZ2004189A3 (cs) 2004-05-12
PE20030433A1 (es) 2003-05-24
RU2004102395A (ru) 2005-05-27
CN1231264C (zh) 2005-12-14

Similar Documents

Publication Publication Date Title
HUP0401046A2 (en) Liquid formulation comprising cetuximab and a fatty acid ester of polyoxyethylene sorbitan
AU2002240400A1 (en) Free-standing baking receptacle and methods of use
HK1157760A1 (en) Benzimidazol-carbonyl-pyridinyl-amino-propionic acid ethyl ester hemihydrate and use thereof
IL158765A0 (en) Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors
AU2002213140A1 (en) Gaming bonus device and method of use
AU2001294920A1 (en) Chrono delivery formulations and method of use thereof
AU2000278326A1 (en) Interactive and animated mini-theater and method of use
AU3591301A (en) Ester derivatives of dimethylpropionic acid and pharmacetuical compositions containing them
AU2003239919A1 (en) Intravenous rifalazil formulation and methods of use thereof
AU2003222083A1 (en) Acid and ester compounds and methods of using the same
HK1067312A1 (en) Pharmaceutical composition comprising a lipase inhibitor and a sucrose fatty acid ester
AU8235601A (en) Dispenser and method of use
AU2002346923A1 (en) Inhibitor mixture for (meth)acrylic acid and (meth)acrylic acid ester
AU2002315225A1 (en) Fastener remover and method of use
AU2002246608A1 (en) Compositions containing heteropolymers and oil-soluble esters and methods of using same
AU2001280646A1 (en) Display and method of manufacture
AU2002308979A1 (en) Acrylic esters and use thereof
AU2002246926A1 (en) 12-hydroxy-eicosatrienoic acid analogs and methods of use thereof
EP1578348A3 (en) Formulation comprising bioactive agents and method of using same
AU2002228711A1 (en) Hydroxy-alkanoic acid ester monomer compositions and methods of making same
AU2002354848A1 (en) Liquid formulation comprising Cetuximab and a fatty acid ester of polyoxyethylene sorbitan
GB0125872D0 (en) Point of sale display device
AU2001249692A1 (en) Phospholipid scramblases and methods of use thereof
AU2002253050A1 (en) Acid macromonomers and their method of preparation
GB0221236D0 (en) A display device and method of providing same

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees